TACE术后联合斑蝥酸钠维生素B6治疗原发性肝癌患者近期疗效研究
Venous administration of vitamin B6 sodium cantharidate after TACE in the treatment of patients with primary liver cancer
杨帆 1杨军 1濮忠健 1胡雪星2
作者信息
- 1. 226600 江苏省海安市中医院肿瘤科
- 2. 南通大学第二附属医院肿瘤科
- 折叠
摘要
目的 探讨肝动脉灌注化疗栓塞(TACE)术后联合斑蝥酸钠维生素B6 治疗原发性肝癌(PLC)患者的近期疗效.方法 2019 年1 月～2022 年1 月我院收治的 84 例PLC患者,对照组 42 例接受TACE治疗,另 42 例观察组接受TACE术后联合斑蝥酸钠维生素B6 静脉滴注治疗,术后随访1 年.采用化学荧光法检测血清甲胎蛋白(AFP)水平,采用化学发光免疫分析法检测血清糖类抗原125(CA125)水平,采用直接化学发光法检测血清糖类抗原199(CA199)水平,采用酶法检测血清同型半胱氨酸(Hcy)水平,采用硝酸盐还原法检测血清一氧化氮(NO)水平,采用增强化学发光免疫分析法检测血清内皮素(ET-1)水平.结果 观察组完全缓解率、部分缓解率、疾病稳定率和疾病进展率分别为 7.1%、42.9%、38.1%和4.8%,而对照组则分别为7.1%、40.5%、19.1%和26.2%,其中观察组疾病稳定率显著高于对照组(P＜0.05);治疗后,观察组血清AFP、CA125 和CA199 水平分别为(540.4±87.1)μg/L、(28.1±9.1)kU/L和(18.0±4.8)kU/L,显著低于对照组[分别为(831.2±94.8)μg/L、(36.0±10.4)kU/L和(24.1±4.6)kU/L,P＜0.05];观察组血清Hcy和ET-1水平分别为(14.1±3.6)μmol/L和(66.1±10.3)ng/L,显著低于对照组[分别为(18.4±4.3)μmol/L和(80.2±12.1)ng/L,P＜0.05];观察组胃肠道反应发生率为 16.7%,显著低于对照组的 40.5%(P＜0.05);两组 1a 生存率无显著性差异(84.2%对76.9%,P＞0.05).结论 在TACE术后应用斑蝥酸钠维生素B6 静脉滴注可以减轻胃肠道反应,并可能改善内皮细胞功能.
Abstract
Objective This clinical trial was conducted to investigate the efficacy of venous administration of vitamin B6 sodium cantharidate after transhepatic arterial chemoembolization(TACE)in the treatment of patients with primary liver cancer(PLC).Methods 84 patients with PLC were encountered in our hospital between January 2019 and January 2022,and 42 patients in the control received TACE and another 42 patients in the observation were treated by TACE followed by venous administration of vitamin B6 sodium cantharidate for three weeks.All patients in the two groups were followed-up for one year.Serum alpha-fetoprotein(AFP)levels were detected by chemical fluorescence assay,serum carbohydrate antigen 125(CA125)levels were detected by chemiluminescence immunoassay,and serum carbohydrate antigen 199(CA199)levels were detected by direct chemiluminescence assay.Serum homocysteine(Hcy)levels were detected by enzymatic method,serum nitric oxide(NO)levels were assayed by nitrate reduction method,and serum endothelin(ET-1)levels were determined by enhanced chemiluminescence immunoassay.Results The CR,PR,SD and PD in the observation were 7.1%,42.9%,38.1%(P＜0.05)and 4.8%,while those in the control were 7.1%,40.5%,19.1%and 26.2%,with the SD significantly different between the two groups;after treatment,serum AFP,CA125 and CA199 levels in the observation group were(540.4±87.1)μg/L,(28.1±9.1)kU/L and(18.0±4.8)kU/L,all significantly lower than[(831.2±94.8)μg/L,(36.0±10.4)kU/L and(24.1±4.6)kU/L,respectively,P＜0.05]in the control;serum Hcy and ET-1 levels were(14.1±3.6)μmol/L and(66.1±10.3)ng/L,both much lower than[(18.4±4.3)μmol/L and(80.2±12.1)ng/L,respectively,P＜0.05]in the control;the incidence of gastrointestinal reaction in the observation was 16.7%,much lower than 40.5%(P＜0.05)in the control;there was no significant difference as respect to the one-year survival in the two groups(84.2%vs.76.9%,P＞0.05).Conclusion The venous administration of vitamin B6 sodium cantharidate after TACE in the treatment of patients with PLC could ameliorate gastrointestinal reactions and improve the vascular endothelial functions.
关键词
原发性肝癌/肝动脉灌注化疗栓塞术/斑蝥酸钠维生素B6/治疗Key words
Hepatoma/Transhepatic arterial chemoembolization/Vitamin B6 sodium cantharidate/Therapy引用本文复制引用
基金项目
江苏省卫生健康委科研项目(M2021096)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据